Disease is an infectious disease, caused as a result of bacterium – Borrelia burgdorferi, which is transmitted to humans through bites of infected adult black-legged ticks. Most human infections are as a result of bites of nymphs (immature tick). Ticks can put on any part of the human body and can transmit the infection, if attached to the host body for 36 to 48 hours. Blacklegged ticks are accountable for spreading Lyme disease in the northeastern, mid-Atlantic, and north-central aspects of the U.S. However, western black-legged ticks spread Lyme disease in the regions over the Pacific Coast. These regions are thus, anticipated to witness rapid growth of industry for Lyme disease treatment in the near future.
The major players operating in the Lyme Disease Treatment Market include Lupin Ltd, Mylan N.V., Sun Pharmaceuticals Industries Ltd., Pfizer Inc., G&W Laboratories, Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, GlaxoSmithKline plc., and Hospira Inc.
Antibiotics are found to be the utmost effective treatment for Lyme disease. Patients with early stages of Lyme disease recover rapidly and completely with appropriate antibiotics such as as an example doxycycline, amoxicillin, and cefuroxime axetil. Patients with certain neurological or cardiac illness could be treated with intravenous ceftriaxone. Patients bearing chronic symptoms of Lyme disease for over 6 months, can recover within a few weeks, through oral antibiotic treatment.
Read More@ https://bit.ly/388oVuN
